Can maternal exposure to carbon black nanoparticles affect male fertility?

| March 18, 2019

article image
Carbon black nanoparticles are manufactured for use in rubber products, as a color pigment in plastics, paint, and ink and used to model exposure to air pollution particles. These particles have been shown to have toxic effects and previous mice studies have shown that maternal exposure can affect the sperm count in male offspring.

Spotlight

Pharmaceutical Manufacturers Association of Turkey / İlaç Endüstrisi İşverenler Sendikası (İEİS)

IEIS was established in 1964 to improve and bolster business conditions of its members and to contribute to the development of healthcare policies in Turkey. Pharmaceutical production is the primary activity of our local and multinational members. We cater to a diverse group of companies with different business interests stretching from originator products to branded generics, manufacturing and importing of pharmaceuticals and active ingredients, marketing of biological products (blood products, vaccines, etc.) as well as contract manufacturers.

OTHER ARTICLES

A pharma outsourcing mission

Article | August 18, 2021

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Spotlight

Pharmaceutical Manufacturers Association of Turkey / İlaç Endüstrisi İşverenler Sendikası (İEİS)

IEIS was established in 1964 to improve and bolster business conditions of its members and to contribute to the development of healthcare policies in Turkey. Pharmaceutical production is the primary activity of our local and multinational members. We cater to a diverse group of companies with different business interests stretching from originator products to branded generics, manufacturing and importing of pharmaceuticals and active ingredients, marketing of biological products (blood products, vaccines, etc.) as well as contract manufacturers.

Events